-
11.发明申请公开(公告)号：US20190387710A1
公开(公告)日：2019-12-26
申请号：US16563022
申请日：2019-09-06
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand Jal Unwalla
IPC: A01K5/01 , B65D25/18 , B65D25/04 , B65D1/36 , B65D1/34 , A01K7/00 , B65D77/20 , A23K20/00 , A23K50/48 , C07D471/04 , C07D401/14
Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
-
公开(公告)号：US20190270751A1
公开(公告)日：2019-09-05
申请号：US16411679
申请日：2019-05-14
Applicant: Pfizer Inc.
Inventor： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC: C07D491/056 , C07F7/18 , A61K31/4015 , C07D207/267 , C07D207/08 , C07D209/52 , C07D498/04 , C07D207/273 , C07D263/24 , C07D239/88 , C07D239/86 , C07C69/94 , C07D217/24 , C07D217/22 , C07D217/02 , C07D405/14 , C07D401/14 , C07D487/04 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D207/26 , C07D215/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/14 , C07D413/12 , C07D417/12 , A61K31/40
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US10336748B2
公开(公告)日：2019-07-02
申请号：US15546887
申请日：2016-01-29
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand J. Unwalla
IPC: C07D471/04
Abstract: The present invention provides methoxy-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
-
公开(公告)号：US10316018B2
公开(公告)日：2019-06-11
申请号：US16206166
申请日：2018-11-30
Applicant: PFIZER INC.
Inventor： Katherine Lin Lee , Christophe Philippe Allais , Christoph Martin Dehnhardt , Lori Krim Gavrin , Seungil Han , David Hepworth , Arthur Lee , Frank Eldridge Lovering , John Paul Mathias , Dafydd Rhys Owen , Nikolaos Papaioannou , Eddine Saiah , Joseph Walter Strohbach , John David Trzupek , Stephen Wayne Wright , Christoph Wolfgang Zapf
IPC: A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/4745 , A61K31/4015 , A61K45/06 , C07D401/12 , C07D413/04 , C07D207/273 , C07D491/18 , C07D471/04 , C07D413/14 , C07D401/14
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
15.发明申请公开(公告)号：US20190150401A1
公开(公告)日：2019-05-23
申请号：US16268857
申请日：2019-02-06
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand Jal Unwalla
IPC: A01K5/01 , B65D77/20 , B65D25/04 , B65D1/34 , A01K7/00 , B65D25/18 , A23K20/00 , A23K50/48 , B65D1/36
CPC classification number: A01K5/0121 , A01K7/00 , A23K20/00 , A23K50/48 , B65D1/34 , B65D1/36 , B65D25/04 , B65D25/18 , B65D77/2024 , B65D85/70 , B65D2577/205 , C07D401/14 , C07D471/04
Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
-
Patent Agency Ranking
16.发明授权公开(公告)号：US10227346B2
公开(公告)日：2019-03-12
申请号：US15889296
申请日：2018-02-06
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand Jal Unwalla
IPC: A61K31/437 , A61K31/4353 , C07D471/04 , C07D401/14
Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
-
公开(公告)号：US10174000B2
公开(公告)日：2019-01-08
申请号：US15754650
申请日：2016-08-16
Applicant: PFIZER INC.
Inventor： Katherine Lin Lee , Christophe Philippe Allais , Christoph Martin Dehnhardt , Lori Krim Gavrin , Seungil Han , David Hepworth , Arthur Lee , Frank Eldridge Lovering , John Paul Mathias , Dafydd Rhys Owen , Nikolaos Papaioannou , Eddine Saiah , Joseph Walter Strohbach , John David Trzupek , Stephen Wayne Wright , Christoph Wolfgang Zapf
IPC: C07D207/273 , C07D401/12 , C07D401/14 , C07D413/04 , C07D413/14 , C07D471/04 , C07D491/18 , A61K31/4015 , A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/4745 , A61K45/06
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US20180002330A1
公开(公告)日：2018-01-04
申请号：US15546887
申请日：2016-01-29
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand J. Unwalla
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: The present invention provides methoxy-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
-
公开(公告)号：US20150284405A1
公开(公告)日：2015-10-08
申请号：US14678114
申请日：2015-04-03
Applicant: Pfizer Inc.
Inventor： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC: C07D491/056 , A61K31/4709 , A61K45/06 , C07D405/12 , C07D215/48 , A61K31/47 , A61K31/4725 , C07D417/12 , A61K31/541 , C07D413/12 , A61K31/5377 , C07D207/26 , A61K31/4015 , C07D407/14 , C07D487/04 , C07D403/12 , A61K31/517 , C07D401/12
CPC classification number: C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物，互变异构体和药学上可接受的盐，其中化合物具有如说明书中定义的式Ia结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
公开(公告)号：US12202836B2
公开(公告)日：2025-01-21
申请号：US18342977
申请日：2023-06-28
Applicant: Pfizer Inc.
Inventor： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC: C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/18
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.04 seconds)
